免疫原性细胞死亡与乳腺癌治疗的研究进展

Research Progress on the Immunogenic Cell Death and the Treatment of Breast Cancer

免疫原性细胞死亡(immunogenic cell death,ICD)是一种特殊形式的细胞死亡,其在乳腺癌的治疗中发挥着重要作用。研究表明,利用特定的化疗药物、放射疗法或靶向药物等治疗乳腺癌时,肿瘤细胞会释放或增加表达损伤相关分子模式(damage associated molecular patterns,DAMPs),激活ICD从而提高肿瘤细胞的免疫原性,募集和激活免疫细胞,进一步激发或增强抗肿瘤免疫反应。本文对利用诱导ICD治疗乳腺癌的相关临床前研究进行总结,为乳腺癌临床治疗方案选择提供参考和思路。

Immunogenic cell death(ICD) is a special form of cell death,which plays an important role in the treatment of breast cancer. Research shows that when specific chemotherapy drugs,radiotherapy or targeted drugs are used to treat breast cancer,tumor cells will release or increase the expression of damage associated molecular patterns(DAMPs),activate ICD,thereby improving the immunogenicity of tumor cells,recruiting and activating immune cells,and further stimulate or enhance anti-tumor immune response. This article summarizes the relevant preclinical studies on the use of induced ICD in the treatment of breast cancer,and provides a reference for the design of breast cancer therapy in the future.